Vascular effects, efficacy and safety of nintedanib in patients with advanced, refractory colorectal cancer: a prospective phase I subanalysis

by Mross, Klaus, Büchert, Martin, Frost, Annette, Medinger, Michael, Stopfer, Peter, Studeny, Matus, Kaiser, Rolf
Published 2014

A Phase I, open-label, dose-escalation study of continuous once-daily oral treatment with afatinib in patients with advanced solid tumors

by Gordon, Michael S., Mendelson, David S., Gross, Mitchell, Uttenreuther-Fischer, Martina, Ould-Kaci, Mahmoud, Zhao, Yihua, Stopfer, Peter, Agus, David B.
Published 2012

A Phase I, open-label, dose escalation study of afatinib, in a 3-week-on/1-week-off schedule in patients with advanced solid tumors

by Marshall, John, Hwang, Jimmy, Eskens, Ferry A. L. M., Burger, Herman, Malik, Shakun, Uttenreuther-Fischer, Martina, Stopfer, Peter, Ould-Kaci, Mahmoud, Cohen, Roger B., Lewis, Nancy L
Published 2012

Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment

by Schnell, David, Buschke, Susanne, Fuchs, Holger, Gansser, Dietmar, Goeldner, Rainer-Georg, Uttenreuther-Fischer, Martina, Stopfer, Peter, Wind, Sven, Petersen-Sylla, Marc, Halabi, Atef, Koenen, Rüdiger
Published 2014